› Forums › General Melanoma Community › Yervoy / PD 1 trial
- This topic has 18 replies, 4 voices, and was last updated 12 years, 4 months ago by JerNYC.
- Post
- Replies
-
-
- November 4, 2011 at 10:31 am
I don't know of anybody off hand, but I hope you get some replies. We are looking to get Dave into this trial after he gets off of the steroids.
Best wishes,
Maria
-
- November 6, 2011 at 4:45 am
Things often get slow on the weekends. Do rremember that you asked abut a specifi trial an specifi locations, not bout people that have tried or am now trying PD-1 otherwise. (I would like to hear more about the trial to.)
-
- November 6, 2011 at 3:47 pm
I was on the anti-PD-1 trial until about a month ago when my scans showed quite a lot of progression.
I immediately went onto Ipi as my oncologist believed that such a course of action would be broadly equivalent to being on the combined trial, because anti-PD-1 stays on the receptors for some period of time quite longer than the blood half-life would indicate (I believe I was told 3-6 months). I had my second Ipi infusion last week.
Maybe (and this is just supposition) the reason for so little information out there on the combined trial are the tiny patient numbers involved. In my case I have had a number of questions about actual or likely side effects from the combination (if indeed what I'm doing can be deemed to be akin to the combo) and the answer I generally get back is that the "n" is too small at this stage to draw conclusions. The only more specific piece of information I received concerned the ALC. When my ALC dipped last week (not at infusion time but a few days afterwards – I had to have extra bloodwork due to a separate complication) my Dr told me that they have observed some modulation of ALC in patients on the combined trial, and they believe it is the result of the anti-PD-1. He told me not to be concerned just yet.
From my perspective I feel like I am experiencing a greater number and/or intensity of side effects now than I was when I was on anti-PD-1. I guess it could also be symptoms of disease progression, but trying to stay optimistic for now that it is side effects.
J
-
- November 6, 2011 at 3:47 pm
I was on the anti-PD-1 trial until about a month ago when my scans showed quite a lot of progression.
I immediately went onto Ipi as my oncologist believed that such a course of action would be broadly equivalent to being on the combined trial, because anti-PD-1 stays on the receptors for some period of time quite longer than the blood half-life would indicate (I believe I was told 3-6 months). I had my second Ipi infusion last week.
Maybe (and this is just supposition) the reason for so little information out there on the combined trial are the tiny patient numbers involved. In my case I have had a number of questions about actual or likely side effects from the combination (if indeed what I'm doing can be deemed to be akin to the combo) and the answer I generally get back is that the "n" is too small at this stage to draw conclusions. The only more specific piece of information I received concerned the ALC. When my ALC dipped last week (not at infusion time but a few days afterwards – I had to have extra bloodwork due to a separate complication) my Dr told me that they have observed some modulation of ALC in patients on the combined trial, and they believe it is the result of the anti-PD-1. He told me not to be concerned just yet.
From my perspective I feel like I am experiencing a greater number and/or intensity of side effects now than I was when I was on anti-PD-1. I guess it could also be symptoms of disease progression, but trying to stay optimistic for now that it is side effects.
J
-
- November 6, 2011 at 3:47 pm
I was on the anti-PD-1 trial until about a month ago when my scans showed quite a lot of progression.
I immediately went onto Ipi as my oncologist believed that such a course of action would be broadly equivalent to being on the combined trial, because anti-PD-1 stays on the receptors for some period of time quite longer than the blood half-life would indicate (I believe I was told 3-6 months). I had my second Ipi infusion last week.
Maybe (and this is just supposition) the reason for so little information out there on the combined trial are the tiny patient numbers involved. In my case I have had a number of questions about actual or likely side effects from the combination (if indeed what I'm doing can be deemed to be akin to the combo) and the answer I generally get back is that the "n" is too small at this stage to draw conclusions. The only more specific piece of information I received concerned the ALC. When my ALC dipped last week (not at infusion time but a few days afterwards – I had to have extra bloodwork due to a separate complication) my Dr told me that they have observed some modulation of ALC in patients on the combined trial, and they believe it is the result of the anti-PD-1. He told me not to be concerned just yet.
From my perspective I feel like I am experiencing a greater number and/or intensity of side effects now than I was when I was on anti-PD-1. I guess it could also be symptoms of disease progression, but trying to stay optimistic for now that it is side effects.
J
-
- November 6, 2011 at 4:45 am
Things often get slow on the weekends. Do rremember that you asked abut a specifi trial an specifi locations, not bout people that have tried or am now trying PD-1 otherwise. (I would like to hear more about the trial to.)
-
- November 6, 2011 at 4:45 am
Things often get slow on the weekends. Do rremember that you asked abut a specifi trial an specifi locations, not bout people that have tried or am now trying PD-1 otherwise. (I would like to hear more about the trial to.)
-
- You must be logged in to reply to this topic.